Combination of PI-103 and mTOR inhibitor rapamycin performed a better therapeutic effect than single agents in human ovarian and prostate cancer cells, and can effectively prevent rebound activation of the Akt pathway after rapamycin treatment41. Here, MTOR is linked to Familial prostate cancer.